PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Joins Forces with Adelia Therapeutics to Potentially Address Treatment Gaps Beyond Major Depressive Disorder
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, today announced the close of its acquisition of 100% of the shares in Adelia Therapeutics Inc. for up to CA$20,161,575 (approximately US$15.75 million). “We are thrilled to join forces with Adelia. We see this acquisition as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” said Cybin CEO Doug Drysdale. “Adelia’s focuses on novel delivery methods and innovative therapies may contribute to our goal of therapies with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods, and reduced side…